ReviewClinical microbiology reviews2001
Vaccination strategies for mucosal immune responses.
Review in Clinical microbiology reviews, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 390 citations in OpenAlex.
- Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.PLoS neglected tropical diseases · 2018Trial
- The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.Infection and immunity · 2005Trial
- Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine.Infection and immunity · 2005Trial
- Advances in Polyethyleneimine-Derived Nanoformulations.Small science · 2026Review
- Animal models for enterovirus 71: Mechanisms, immunity, and applications.Human vaccines & immunotherapeutics · 2025Review
- Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases.Acta pharmaceutica Sinica. B · 2025Review
- Immunization of pigs with Actinobacillus pleuropneumonia live attenuated (gene-deleted) vaccine HB04M intramuscularly or intranasally exhibits remarkably rapid protection against heterologous strain challenge.BMC veterinary research · 2025Article
- Single-dose intranasal AdC68-vectored vaccines rapidly protect Syrian hamsters against lethal Nipah virus infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- Is Lactococcus lactis a Suitable Candidate for Use as a Vaccine Delivery System Against Helicobacter pylori?Current microbiology · 2024Review
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251.Nature communications · 2023Article
- Biodistribution and Adjuvant Effect of an Intranasal Vaccine Based on Chitosan Nanoparticles against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Oral vaccination as a potential strategy to manage chronic wasting disease in wild cervid populations.Frontiers in immunology · 2023Review
- Challenges and opportunities in current vaccine technology and administration: A comprehensive survey examining oral vaccine potential in the United States.Human vaccines & immunotherapeutics · 2022Article
- Polymeric Nanoparticles for Inhaled Vaccines.Polymers · 2022Review
- Article
- Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic.World journal of virology · 2022Review
- Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles ExpressingVaccines · 2022Article
- Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants.Clinical and experimental vaccine research · 2022Review
78 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal administration of vaccines is an important approach to the induction of appropriate immune responses to microbial and other environmental antigens in systemic sites and peripheral blood as well as in most external mucosal surfaces. The development of specific antibody- or T-cell-mediated immunologic responses and the induction of mucosally induced systemic immunologic hyporesponsiveness (oral or mucosal tolerance) depend on complex sets of immunologic events, including the nature of the antigenic stimulation of specialized lymphoid structures in the host, antigen-induced activation of different populations of regulatory T cells (Th1 versus Th2), and the expression of proinflammatory and immunoregulatory cytokines. Availability of mucosal vaccines will provide a painless approach to deliver large numbers of vaccine antigens for human immunization. Currently, an average infant will receive 20 to 25 percutaneous injections for vaccination against different childhood infections by 18 months of age. It should be possible to develop for human use effective, nonliving, recombinant, replicating, transgenic, and microbial vector- or plant-based mucosal vaccines to prevent infections. Based on the experience with many dietary antigens, it is also possible to manipulate the mucosal immune system to induce systemic tolerance against environmental, dietary, and possibly other autoantigens associated with allergic and autoimmune disorders. Mucosal immunity offers new strategies to induce protective immune responses against a variety of infectious agents. Such immunization may also provide new prophylactic or therapeutic avenues in the control of autoimmune diseases in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.